Fig. 7

Effects of BPA, Tm and 4-PBA on the inflammatory response and barrier function in OTCs at 24 h. A Cytokine concentrations (IL-1β, TNF-α and IL-6). B Inflammatory response-related genes. C Barrier function-related gene levels. D Typical immunoblots showing inflammatory response-related proteins. E Inflammatory response-related proteins. F Typical immunoblots exhibiting barrier function-related proteins. G Barrier function-related protein levels. Data are presented as means ± SEM, n = 6. Means with no common letter are different (P < 0.05). BPA group, OTCs treated with 400 μmol/L bisphenol A (BPA); BPA + Tm, OTCs treated with 400 μmol/L BPA + 0.5 μg/mL tunicamycin (Tm; ERS activator); BPA + 4-PBA, OTCs treated with 400 μmol/L BPA + 1 μmol/L 4-phenyl butyric acid (4-PBA; ERS antagonist); CON, OTCs treated with DMEM/F12 complete medium; IL, interleukin; MyD88, myeloid differentiation factor 88; NF-κB, nuclear factor kappa-B; OTCs, ovine trophoblast cells; TLR, toll-like receptor; TER, transepithelial electrical resistance; TNF, tumour necrosis factor; ZO-1, zonula occludens-1